Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Asset icon - trade crypto, stocks, and gold on Pluang

Buy & Sell BridgeBio Pharma Inc (BBIO) – BridgeBio Pharma Inc Price Today

24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

BridgeBio Pharma (BBIO) trades at $66.13, down 5.07% on the day, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q1 2026 revenue of $502.08M but missed EPS expectations with a loss of $0.84 per share. Recent developments include FDA NDA submission for encaleret and positive pipeline updates, though the company continues to operate with negative cash flow and significant losses.
Despite strong analyst support (96% buy ratings) and a $102.63 consensus price target, BBIO faces substantial execution risks with negative profitability, high debt load, and cash burn. The stock offers speculative upside potential from pipeline catalysts but requires careful risk management given the company's financial challenges and competitive biopharmaceutical landscape.
Read full analysis

Key Stats

  • Market Cap
    $12.95B
  • Sector
    Health
  • 3M Drawdown
    -17%
  • Enterprise Value
    $14.50B
  • Dividend Yield
    -
  • Typical Hold Time
    58 days
$66.12
52W Low: $32.26
28 May 2025
52W High: $79.91
22 Jan 2026

BridgeBio Pharma Inc (BBIO) is currently valued at a market capitalization of $12.95B, with an enterprise value of $14.50B. Over the past 52 weeks, BridgeBio Pharma Inc has traded between a low of $32.26 and a high of $79.91, highlighting its annual price range. Over the past three months, BridgeBio Pharma Inc has recorded a drawdown of -17%, reflecting recent price volatility. On average, investors hold BridgeBio Pharma Inc for approximately 58 days, indicating typical investor behavior on the platform.

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.


Technical Indicators
|
|
|
Overall Summary
Bearish (17)Neutral (4)Bullish (6)

People also bought


US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions

Key Stats

  • Market Cap
    $12.95B
  • Sector
    Health
  • 3M Drawdown
    -17%
  • Enterprise Value
    $14.50B
  • Dividend Yield
    -
  • Typical Hold Time
    58 days
$66.12
52W Low: $32.26
28 May 2025
52W High: $79.91
22 Jan 2026

BridgeBio Pharma Inc (BBIO) is currently valued at a market capitalization of $12.95B, with an enterprise value of $14.50B. Over the past 52 weeks, BridgeBio Pharma Inc has traded between a low of $32.26 and a high of $79.91, highlighting its annual price range. Over the past three months, BridgeBio Pharma Inc has recorded a drawdown of -17%, reflecting recent price volatility. On average, investors hold BridgeBio Pharma Inc for approximately 58 days, indicating typical investor behavior on the platform.

Let’s invest in this asset by signing up or download!